17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Swiss pharma giant Roche today announced that Dr William Pao, head of Roche pharma research and early development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the USA, effective March 18, 2022. 2 February 2022
Danish diabetes giant Novo Nordisk has reported net sales of 140 billion kroner ($21.3 billion) in 2021, an 11% increase from the year before. 2 February 2022
The top 20 global innovative biopharma companies had a favorable year in 2021, reporting a 24.9% growth in aggregate market capitalization (MCAP), according to GlobalData. 1 February 2022
Byannli (paliperidone palmitate) has been approved in Great Britain for the maintenance treatment of schizophrenia in adults who are clinically stable on one-monthly or three-monthly paliperidone palmitate. 1 February 2022
Pennsylvania, USA-based liver disease specialist Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced positive results from a trial in non-alcoholic steatohepatitis (NASH). 1 February 2022
New jobs in the UK life sciences sector hit all-time highs in 2021 amid a record injection of government healthcare funding to position Britain as a global life sciences superpower post-Brexit, according to new research. 1 February 2022
The first month of the year is often one of the busiest for the announcement of mergers and acquisitions (M&A) in the pharmaceutical sector. 31 January 2022
Thousands of those most at-risk to COVID-19 will soon be able to access the UK’s second ground-breaking antiviral, the Department of Health and Social Care announced on Friday. 31 January 2022
Tokyo-based drugmaker Kyowa Kirin has submitted for Japanese approval for Mitomycin-C (mitomycin) as a topical ophthalmic drug for use in glaucoma surgery. 31 January 2022
Japanese drug major Shionogi edged up 2.4% to 6,464 yen this morning, as it presented the results up to day six of the Phase IIa part of a Phase II/III clinical trial of S-217622, an orally administered antiviral drug for COVID-19. 31 January 2022
French ophthalmology specialist Laboratoires Théa has signed an agreement to purchase seven branded ophthalmic products from Akorn Operating Company. 31 January 2022
US pharma Eli Lilly saw its shares close up 3.5% at $245.10 on Friday, after it announced plans to significantly expand production facilities in the USA and Ireland. 29 January 2022
Following the January meeting of the European Medicines Agency’s Medicinal Products for Human Use (CHMP) several drug recommendations were announced. 28 January 2022
Trade group Medicines Australia has called for the country’s government to deliver a plan that shortens the time that patients wait for access to the latest innovative treatments and vaccines. 28 January 2022
Texan firm TFF Pharmaceuticals, a biopharma developing and commercializing drugs based on its thin film freezing technology platform, has completed enrollment of 40 healthy subjects in its Phase I trial of a dry powder formulation of niclosamide, an antiviral with potential in COVID-19 and other respiratory viral diseases. 27 January 2022
Steve Kent, chairman at Pharmaspectra, a data business with a focus on medical affairs, provides an Expert View on the increasing impact of data in medicine. 27 January 2022
A 30% drop in the share price of Alzheimer’s specialist Cortexyme has followed news of an abrupt change to its clinical research priorities. 27 January 2022
Russia plans to begin the production of a scarce drug based on ethosuximide for the treatment of epilepsy, according to recent statements by some of local analysts in the field of pharmaceutics and Russian media, reports The Pharma Letter’s local correspondent. 26 January 2022
Swiss contract development and manufacturing organization (CDMO) Lonza has reported full-year 2021 sales of 5.4 billion francs ($5.9 billion). 26 January 2022
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.